Related Experiment Video
Updated: Aug 15, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Percutaneous occlusion of patent ductus arteriosus with Rashkind device. 4-year follow-up]
J Munayer Calderón1, G Maza Juárez, T Aldana Pérez
1Departamento de Hemodinamia, Hospital General CMN La Raza, Sur 69B No. 109, Col. Prado Ermita, 09480 México, D.F.
Insights
The Rashkind device effectively closes the patent ductus arteriosus (PDA) in pediatric patients. This study shows a high occlusion rate and minimal complications, establishing it as a safe treatment option.
Area of Science:
- Cardiovascular Medicine
- Pediatric Cardiology
- Interventional Cardiology
Context:
- Patent ductus arteriosus (PDA) is a common congenital heart defect requiring intervention.
- The Rashkind device offers a transcatheter approach for PDA closure.
- Evaluating the long-term efficacy and safety of the Rashkind device is crucial.
Purpose:
- To assess the outcomes of ductus arteriosus closure using the Rashkind device.
- To determine the occlusion rates and incidence of residual leaks post-implantation.
- To report on the safety profile and complications associated with the Rashkind device.
Summary:
- Sixty-six Rashkind devices were implanted in 63 pediatric patients (mean age 8.2 years).
- Echocardiography assessed duct diameter, morphology, and residual leaks at various follow-up intervals.
- Occlusion rates reached 68% at 24 hours and 92% at one year, with low complication rates.
Impact:
- The Rashkind device demonstrates a safe and effective method for treating patent ductus arteriosus.
- High success rates suggest the Rashkind device is a viable alternative to surgical closure.
- Further research can explore optimal patient selection and device sizing for PDA treatment.
Abstract:
We present the results and follow up of ductus arteriosus closure with the Rashkind device. Sixty-six devices were implanted in 63 patients, 41 women and 22 men, with a mean age of 8.2 years. We determined the diameter of the duct, the presence or absence of immediate residual leak at 3 months, 6 months, 1 year, and every year of follow-up by ecocardiography. The hemodynamic determinations showed: type A morphology in 49, type C in 7 and type E in 7; with a mean diameter of 4.2 +/- 1.4 mm (range of 2.3 to 8.7 mm) and a Qp/Qs 2.2 +/- 1.5 (range 0.7 to 8.6). Forty-five 17 mm devices and 18 of 12 mm were used. The incidence of immediate residual leak was 65% (n-41); at 24 hrs. Post-procedure was 31.7% (n-20) and at one year 7.9% (n-5). Three patients with persistent leak had implantation of a second Rashkind device and one more patient an endovascular coil, the other patient is waiting for a second occlusor. Minor complications occurred in 15.8% (n-10). Results show an occlusion rate at 24 hrs of 68% and at one year of 92%; no patient presented migration of the device, hemolysis or obstruction of the pulmonary artery branches. We consider that occlusion of the ductus arteriosus with the Rashkind device is a safe and effective option for the treatment of this pathology.
